#clinical trial — Wednesday, October 07, 2026 (1 items)
| 21 | ℹ |
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
(linkinghub.elsevier.com)
|
Cell Metabolism 2026-10-07 | #clinical trial #obesity #metabolic #pharmacology #cardiovascular |